Objective: To assess growth, tolerance, and biochemical measures of protein status in term infants fed an experimental formula with reduced total protein concentration and enriched in bovine alpha-lactalbumin prepared from an alpha-lactalbumin dominant bovine whey. Methods: Healthy, term, exclusively formula-fed infants Յ14 days postnatal age, between 10th and 90th percentiles in weight and length for age were studied in this randomized, masked, multicenter study. Infants received ad libitum feedings of either experimental or control formula for 12 weeks. Adverse events and acceptability of formulas were assessed every 2 weeks. Weight, length, and head circumference were measured at baseline and every 4 weeks. Serum creatinine, albumin, and blood urea nitrogen were assessed at baseline and study completion. Anthropometric measures were compared to Centers for Disease Control reference ranges using Z scores.
ence during the study. Mean serum albumin and blood urea nitrogen (BUN) levels were similar at study initiation. At study completion, serum albumin levels were the same in both groups, whereas BUN was significantly higher in infants fed control formula (P ‫ס‬ 0.0016). More infants fed control (n ‫ס‬ 20) than experimental (n ‫ס‬ 15) formula discontinued the study because of adverse events. There were no differences in the adverse event profiles of the groups completing the study. Most of the adverse events were mild and resolved without treatment or sequelae. Acceptability and tolerance of the experimental formula was greater than the control formula, except at 2 weeks. Unacceptable ratings ranged from 0% to 10% (mean, 4.1%) in the experimental formula group and from 1.6% to 14.1% (mean, 7.0%) in the control formula group. Conclusions: Growth and serum albumin were comparable in infants fed experimental and control formulas for the first 12 weeks of life, suggesting adequate protein nutrition from the alpha-lactalbumin-rich formula, despite its lower total protein content. Growth and adverse events data support the safety of the experimental formula. Fewer discontinuations and unsatisfactory ratings among infants fed the experimental formula suggest that it is better tolerated than control formula. The recommended diet for newborn infants is human milk (1) (2) (3) . Infant formulas, developed to replace or supplement human milk, have been modified with the goal of being as close as possible to human milk in composition and physiologic benefits (4) . Bovine milk and its fractions, such as demineralized whey, are the primary ingredients of most infant formulas. There are important differences between the protein content and composition of bovine and human milk, and some of these differences remain in current infant formulas. These differences are reflected in essential amino acid composition. To meet the amino acid needs of the neonate, the total protein content of most infant formulas (traditionally 15 g/L for typical bovine milk-based formula) is higher than that of human milk (9-11 g/L) (4).
The higher concentration of protein in infant formulas provides the infant with amino acids in excess of the amount required for maintenance and growth. The excess amino acid load must be catabolized and the nitrogen excreted as urinary urea.
In addition to its lower total protein content, human milk also has a protein composition different from bovine milk, with a higher concentration of whey proteins (approximately 60% of total protein after the first month of lactation) than bovine milk (20% of total protein) (5). Among whey proteins in human milk, alpha-lactalbumin, the most prominent component, comprises approximately 20% to 25% of the total protein content (2-3 g of the 9-11 g total protein/L) (6), whereas only 2%-3% of bovine milk protein is alpha-lactalbumin (5). Alphalactalbumin is rich in essential amino acids (63% of total amino acids, compared with 52% of total amino acids in bovine milk protein) (7) . In particular, alpha-lactalbumin has a high content of tryptophan and cysteine.
Using whey processed by a milk-separation technique, in which adjustments in pH and temperature selectively promote the precipitation of beta-lactoglobulin, a new infant formula with a modified protein composition has been developed. In the current study, we compared this lower protein infant formula, which contains more bovine alpha-lactalbumin, to a standard bovine wheydominant infant formula. Growth, tolerance, and safety were evaluated in healthy, full-term infants during the first 12 weeks of postnatal life, in part to satisfy regulatory requirements for a new formula (8) .
MATERIALS AND METHODS
A prospective, multicenter, masked, randomized clinical trial was undertaken to compare infant growth, safety, and tolerance of a standard whey-dominant control formula (CF) with that of an experimental formula (EF) containing lower total protein and increased alpha-lactalbumin concentrations. The study was conducted in accordance with Good Clinical Practice (GCP) and the Declaration of Helsinki (ICH). The institutional review boards (IRBs) of the participating centers approved the study protocol. Written informed consent was obtained from the parent or legal guardian of each infant before enrollment. The study tested the hypothesis that infants fed EF would have comparable growth and acceptability when compared with infants fed CF.
Study Population
Infants Յ14 days postnatal age were included if they were healthy, born at term, and appropriate for gestational age; had birth weight and length within the 10th and 90th percentiles for age according to growth charts provided by the National Center for Health Statistics (NCHS); had weight and length at enrollment within the 10th and 90th percentiles for age according to NCHS growth charts; and were exclusively fed infant formula. Infants were excluded if they were partially or exclusively fed human milk within 2 days of enrollment; were routinely fed either baby food or solid foods; had siblings with feeding problems that had necessitated a change from a bovine milk-based formula to a protein hydrolysate or soy formula; had conditions that required feedings other than those specified in the protocol; had any diarrheal episode before enrollment; had any major congenital malformation; had suspected or documented systemic or congenital infections (such as human immunodeficiency virus); had cardiac, respiratory, hematologic, gastrointestinal, or other systemic diseases; or had participated in another clinical trial. All routine immunizations, vitamin supplements, and over-the-counter medications were permitted. Mineral supplements (except fluoride) were prohibited.
Study Feedings
The protein compositions of human milk, bovine milk, and the EF and CF are outlined in Figure 1 . Total protein concentration was 14.4 g/L in EF and 15.1 g/L in CF. EF was prepared with half of the protein provided by unmodified bovine milk and half provided by an alpha-lactalbumin-enriched whey fraction. No free amino acids were added to either formula. The alpha-lactalbumin concentration of EF was similar to that of human milk. The beta-lactoglobulin concentration of EF was substantially reduced in comparison with that of CF and other current whey-dominant infant formulas. Table 1 outlines the amino acid content of the two study formulas and human milk. There was an increase in the ratio of essential:total amino acids in EF. Final formula concentration of alpha-lactalbumin was 2.2 g/L in EF and 1.2 g/L in CF. The fat content of the formulas was the same (3.6 g/L). EF and CF had identical levels of vitamins, nucleotides, taurine, and the long-chain omega-3 and omega-6 polyunsaturated fatty acids, docosahexaenoic and arachidonic acids. Calcium concentration of EF was 420 mg/L, slightly lower than that of CF (460 mg/L). Both formulas were manufactured by Wyeth Nutrition and supplied in 250-mL Ready-to-Feed Tetrabrik packs (Askeaton, Ireland). To ensure blinding, EF was labeled with one of two colors and CF was labeled with one of two different colors. The sponsors, investigators, and parents were not aware of which formula was being fed.
FIG. 1.
Protein comparison of human milk, bovine milk, and study formulas. Proportion of total casein fraction, alphalactalbumin, beta-lactoglobulin, and other whey proteins in human and bovine milk and in the two study formulas. From Rudolff and Kunz (4) and Jackson et al. (6) .
Randomization
A computerized randomization/enrollment system was used to assign study formula. Infants were randomly assigned to receive EF or CF and received feedings ad libitum for 12 weeks. If an infant was withdrawn from the study, the randomization number and corresponding formula assignment were not reassigned to another infant.
Growth and Safety Variables
Primary growth variables were infant weight (g), length (cm), weight-for-length ratio, and head circumference (cm), each measured at baseline and weeks 4, 8, and 12. Weight and length measurements required two trained examiners, who repeated each measurement twice to confirm accuracy. Wyeth Nutrition provided training and equipment (digital scales, length boards, and head circumference tapes). Infants were weighed without diapers to the nearest 0.01 kg. Supine length measurements required that an assistant hold the head in position while the torso and legs were positioned for measurement (9, 10) . Assessments were done as long as 3 days before enrollment and within 3 days of other time points. Validity has been established for this method (11, 12) .
Primary safety measurements were the adverse events associated with each study formula. An adverse event was defined as any pathology or unintended change in anatomic, metabolic, or physiologic functioning while taking a study formula. These changes were reflected by physical signs, reported symptoms, or laboratory data. Primary safety end points were recorded during scheduled visits at weeks 4, 8, and 12 and by telephone contacts at weeks 2, 6, and 10. Secondary safety end points were protein status measurements of serum albumin, creatinine, and blood urea nitrogen, and the acceptability and tolerance of study formula. Serum mineral markers, calcium, phosphorus, and magnesium were collected to assess metabolic safety. Blood samples were drawn at baseline and at week 12.
Statistical Analysis
Data were analyzed according to the intent-to-treat (ITT) principle. The ITT set included data from all infants who entered the study and received at least one feeding of study formula. All data were analyzed using SAS (Cary, NC) statistical software (13) . Categorical variables were summarized with frequencies and percentages. Continuous variables were summarized with sample number (n), mean, standard deviation (SD), and 95% confidence interval around the mean. Analysis of variance (ANOVA) and covariance (ANCOVA) were used to assess anthropometric data (weight, length, and head circumference) at birth, baseline, and weeks 4, 8, and 12; gestational age and gender at baseline; and protein status (albumin) and laboratory safety data at baseline and week 12. Because the mean body weight at baseline was significantly greater in the infants randomized to EF than in those randomized to CF (Table 2) , baseline body weight was used as a covariate to adjust other analyses. Weight-for-age ratios at baseline and weeks 4, 8, and 12 were used to assess body weight of study infants relative to Centers for Disease Control (CDC) reference curves (14, 15) . CDC reference data were used to analyze these data because they looked at a population of comparable racial and ethnic diversity and the reference data include a mixture of formula-fed and breast-fed infants. Length-for-age and weightfor-length Z scores were evaluated at baseline and week 12. Epi-Info 2000 (CDC, Atlanta, GA) software (version 1.1) was used to determine Z score values (16) . Any infant with a missing value for a particular variable was not included in the analyses involving that variable.
RESULTS
One hundred ninety-three infants were enrolled from 19 centers in the United States and Canada. In most sites, the numbers of infants randomized to the EF and CF groups were almost equal. However, at two sites more than twice as many infants were randomized to CF (one site: 12 for CF, 5 for EF; a second site: 5 for CF, 2 for EF), and at another site more than twice as many infants were randomized to EF (9 for EF, 4 for CF). Figure 2 summarizes the trial profile. Of the 193 enrolled in the study, 98 infants received EF and 95 received CF. Seventy-two (73.5%) infants fed EF and 62 (65.3%) fed CF completed the study. The most common reasons for discontinuing the study were physician/family request and adverse events. Nineteen (19.4%) infants fed EF and 23 (24.2%) infants fed CF discontinued the study because of physician/family request. Fifteen (15.3%) infants fed EF and 20 (21.1%) infants fed CF discontinued the study because of adverse events. Mean duration in the study for infants who discontinued was 38 days for infants fed EF and 51 days for infants fed CF.
Demographic and disposition data are summarized in Table 3 . Fifty (51.0%) infants in the EF group and 51 (53.7%) in the CF group were males (NS). The mean gestational age, birth weight, length, and head circum- ference were similar in the two groups. There were 150 (77%) white infants, 37 (19%) black infants, and 6 (3%) infants of other races. The two study groups had similar racial compositions. All infants in the study had normal growth in weight, length, and head circumference ( Table 2 ). There were no significant differences in gains in weight, length, or head circumference between the two groups during the 12-week study. The average rate of weight gain was 32.0 g/day for infants receiving EF and 31.9 g/day for infants receiving CF. Except for the baseline difference in weight (3,536.4 g for EF v 3,458.5 g for CF), there were no significant differences between the formula groups in any anthropometric measures. Gender post-hoc analyses demonstrated no difference in mean gains in weight, length, or head circumference for male or female infants fed either EF or CF during the study period.
Growth measurements for study infants were compared with CDC reference growth data using Z scores (Fig. 3) . Infants in both the groups grew slightly more in weight, length, and weight-for-length ratios than would be predicted by the CDC reference ranges. However, the differences were not significantly different from a zero Z score. Incremental increases (baseline and weeks 4, 8, and 12) in Z scores did not differ in males or females fed EF compared with those fed CF for weight, length, weight-for-length, or head circumference.
There was no statistically significant difference between the mean serum albumin of the two formula groups at baseline. Mean serum albumin levels increased to a similar degree in both groups from baseline to week 12. Serum creatinine, calcium, phosphorus, magnesium, blood urea nitrogen were measured at baseline and week 12 and were within normal ranges at both study time points (Table 4) . However, there were statistically significant differences in mean blood urea nitrogen (P ‫ס‬ 0.0016, EF lower than CF) and mean serum creatinine (P ‫ס‬ 0.0054, EF lower than CF) between the formula groups at week 12.
The acceptability and tolerance of EF and CF are summarized in Figure 4 . Both EF and CF were accepted and well tolerated by most infants. After week 2, acceptabil-
FIG. 3.
Summary of weight-for-age, length-for-age, and weight-for-length Z scores of EF-and CF-fed infants relative to CDC reference curves. No significant differences between groups were observed. ity and tolerance were greater in infants who received EF. Unacceptable ratings ranged from 0% to 10% in the EF group (average, 4.1%) and from 1.6% to 14.1% in the CF group (average, 7.0%). The difference between the formula groups in percentage of acceptable ratings was statistically significant at week 8 (P < 0.05, post-hoc analysis).
Eighty-eight (89.8%) EF infants and 82 (86.3%) CF infants experienced adverse events (AEs). More infants fed CF (n ‫ס‬ 20) than EF (n ‫ס‬ 15) discontinued because of AEs (Table 3 ). More infants fed CF than EF discontinued because of spitting up (8 v 4), irritability (7 v 3), and flatulence (7 v 4), whereas more infants fed EF than CF discontinued because of constipation (6 v 3). However, there was no statistically significant difference in the AE profiles of the infants who discontinued and those who completed the study. Most of the AEs were mild and resolved without treatment or sequelae. Less than half of the infants in the EF and CF groups had AEs considered to be formula related (42.9% and 46.3%, respectively). The most common formula-related AEs for infants in the EF and CF groups were flatulence (18.4% and 20.0%, respectively) and constipation (22.4% and 15.8%, respectively).
Three infants in the EF group each had one serious adverse event (SAE), none of which were formula related (viral infection, lethargy, and fever). Two infants in the CF group had four SAEs, also not formula related. The types of concomitant medications received by the two groups were similar. The most common concomitant medications given to infants during the study were anilides, antiflatulents, and antibiotics.
DISCUSSION
We evaluated the growth and safety profile of a bovine milk-based formula with an increased concentration of alpha-lactalbumin in healthy term infants (17, 18) . The alpha-lactalbumin-rich formula is closer in composition to human milk than are current formulas because of its lower total protein content and its amino acid profile. Similar increments of growth occurred in CF and EF infants, despite the estimated lower protein intake of the EF group. Overall growth was adequate in both groups as compared with the CDC reference growth data Z scores (Fig. 3) .
Many infants experience gastrointestinal symptoms such as colic, irritability, constipation, flatulence, and regurgitation that are attributed to diet (19) . Maternal beliefs and cultural factors affect these associations. In this study, more infants discontinued the protocol because of AEs in the CF group than the EF group, and withdrawals because of physician and/or family request also were higher in the CF group. The discontinuation data are congruent to the caregiver responses to acceptability and tolerance questions. Although there was not a breastfeeding group in the study, preliminary data (manuscript in preparation) from another infant formula study using both EF and CF as well as breast milk suggest that the percentage of breastfeeding infants experiencing gastrointestinal AEs is not different in nature or frequency from the gastrointestinal AEs in the formulafed groups of this study.
Circulating fractions of calcium, magnesium, and phosphorus account for less than 1% of the total body content. Thus, serum concentrations do not accurately reflect tissue content. Acute and transient fluctuation of serum calcium, magnesium, and phosphorus may occur in response to compartmental shifts, whereas chronic and severely lowered serum concentrations reflect the presence of a deficiency state. Therefore, baseline and week 12 measurements of these biomarkers were selected as sec -FIG. 4 . Percent of satisfactory formula acceptability and tolerance. Acceptability and tolerance of the study formula recorded during scheduled visits at weeks 4, 8, and 12 and by telephone contact at weeks 2, 6, and 10. In a post-hoc analysis, the study formula had superior acceptability and tolerance at week 8 (P < 0.05). ondary safety end points. The similarity of the CF and EF groups provide additional safety data for the EF formula. Protein requirements for the first months of life generally are based on intake estimates and the protein content and amino acid profile of human milk (20) . It is recognized that this method may not accurately reflect the requirements for appropriate growth in all infants. Recently, the recommendations in the 1985 Food and Agriculture Organization/World Health Organization/United Nations report on Energy and Protein Requirements have been criticized in advance of its revision (8) . Among the recommendations for revision was that recommended protein intake during infancy be decreased by 10% to 26%. Recent evidence indicates that maintenance nitrogen needs have been overestimated and that the mean protein content of human milk is not an estimate of the mean protein requirement, but rather is an approximation of the safe level of protein intake for most infants. Dietary Reference Intakes (DRIs) defining the adequate intake of protein for infants between 0 and 6 months have decreased from 2.2 g protein/kg/day (1989 Recommended Dietary Allowances) to 1.52 g protein/kg/day (21) . Protein intake of formula-fed infants has been reported to be 66% to 70% higher than the protein intake of breastfed infants. Lower protein intakes in breastfed infants have shown no evidence of adverse outcomes. This current study is the first to reduce total protein concentration in infant formula by the use of a new whey fractionation method.
CONCLUSION
This study demonstrates that a lower protein infant formula with increased alpha-lactalbumin concentration supports growth as well as a standard whey-dominant formula. Better acceptance and tolerance was verified by direct parental assessment and by fewer discontinuations for adverse events in the alpha-lactalbumin-rich formula group than in the control formula group. EF appears to be closer to the composition of human breast milk because of its increased concentration of alpha-lactalbumin and lower overall protein concentration. Modifications of formula amino acid composition to more closely approach human milk can be achieved by enriching the bovine whey protein fraction of bovine milk-based formula and not just by changing the whey/casein ratio.
